论文部分内容阅读
目的用Meta分析方法评价索拉菲尼治疗肾细胞癌(renal cell carcinoma,RCC)的疗效和安全性。方法运用Pubmed、Medline、Cochrane library、维普数据库(VIP)、中国期刊全文数据库(CNKI)、万方数据库检索索拉菲尼治疗RCC的随机对照临床试验,2013年5月1日检索文献截止,对符合标准的文献进行质量评价和Meta分析。结果收集国外3个随机对照研究,纳入1 157例患者。Meta分析结果显示,索拉菲尼治疗组与对照组相比,治疗RCC的疗效(OR=1.88,95%CI为1.48~2.39)及不良反应(OR=1.68,95%CI为1.27~2.22)均有显著的统计学意义。结论 Meta分析结果显示,索拉菲尼和其他传统的治疗方案相比,在治疗RCC的疗效上具明显优势,但其不良反应事件发生率较高,在临床应用过程中可能需要调整剂量,甚至中断治疗。
Objective To evaluate the efficacy and safety of sorafenib in the treatment of renal cell carcinoma (RCC) by meta-analysis. Methods Randomized controlled clinical trials of sorafenib in the treatment of RCC with Pubmed, Medline, Cochrane library, VIP database, CNKI and Wanfang database were conducted. The search results were searched on May 1, 2013, Standards-compliant literature for quality evaluation and meta-analysis. Results Three randomized controlled studies were collected abroad and included 1 157 patients. Meta-analysis showed that the efficacy of the treatment of RCC (OR = 1.88,95% CI 1.48 to 2.39) and adverse reactions (OR = 1.68, 95% CI 1.27-2.22) compared with the control group, All have significant statistical significance. Conclusions Meta-analysis showed that compared with other traditional treatment regimens, sorafenib has a significant advantage in the treatment of RCC. However, the incidence of adverse reactions is high, and dosage may need to be adjusted during clinical application. Interrupt treatment.